Cell culture fermentation and microbial fermentation as manufacturing routes

Choosing the route and the control strategy

1. Let the molecule choose the host. Proteins requiring human like glycosylation, complex disulphide bonding or secretion of large multimers need mammalian culture. Simpler proteins that fold without those features are faster and much cheaper microbially, and the decision is effectively irreversible.
2. Size oxygen transfer and heat removal for microbial routes. Dense cultures consume oxygen and generate heat at rates that limit scale before volume does. Those two utilities, not vessel size, are what determine whether a process transfers to a given plant.
3. Decide batch, fed batch or continuous with the analytics in mind. Continuous operation raises volumetric productivity and shortens residence time, and it changes what a batch is, how release works and what in process control has to detect. It is a control strategy decision as much as an engineering one.
4. Build comparability into a biosimilar programme from the start. A biosimilar has to match a reference product across an extensive analytical panel, which means the process is developed toward a target rather than toward a specification. That inverts the usual development sequence.
5. Develop the analytical package alongside the process. Identity, purity, charge and size variants, glycan profile, potency and the impurity panel. Characterisation is what turns a product into a well characterised one, and it takes longer than the process work.
6. Fix the process before it becomes expensive to change. Culture mode, host, purification sequence and critical parameters should be settled before clinical material is made, because changing any of them afterwards triggers a comparability exercise.

Utilities decide where a process can run

Two plants with the same nominal vessel volume can differ enormously in what they can actually run, because oxygen transfer capability, cooling and mixing differ. A process characterised only by volume and duration does not tell a receiving site whether it can be run there.

Describe the process in terms of the demands it makes rather than the equipment it was developed on. That is what makes a transfer possible.

Comparability is the recurring cost in a biosimilar manufacturing programme

Every meaningful change to a biologics process, whether route, scale, site or raw material, raises the question of whether the product is the same. Answering that question requires an analytical package and often a study.

The way to keep that cost down is to make the changes early, while there is little clinical material to compare against, and to fix the process before it becomes the thing being defended.

Shake flask cell culture, and what it can and cannot tell you

A shaken flask is the cheapest vessel that mixes and gases a culture, and it answers media and clone screening questions well. What it cannot tell you is anything set by control: pH drifts as lactate accumulates because nothing titrates it, dissolved oxygen falls as density rises because the only supply is surface transfer, and both depend on fill volume, shaking diameter and speed rather than on the process. So a flask result transfers as a ranking, not as a number, and the working discipline is to hold fill, throw and speed constant and record them with the data.

A cell culture incubator price, and what moves it

A basic air jacketed carbon dioxide incubator is the entry point; a water jacket, oxygen control for hypoxia work, a high temperature decontamination cycle, in-chamber humidity and gas sensors of the infrared type, and copper interiors each move the price. Capacity and the number of inner doors matter for contamination control as much as for volume. The running costs are gas, filters and the service contract, and the hidden cost is a failed incubator taking a month of cultures with it, which is the argument for two small units.

A cell bioreactor, and how it differs from a fermenter

A bioreactor for mammalian cells is tuned for gentleness and gas control: a marine or pitched impeller at low tip speed, sparging that will not shear, carbon dioxide in the gas mix for pH, and a working temperature and osmolality that leave little margin. A microbial fermenter is the opposite, high agitation, high oxygen demand and a heavy heat load. The vessel geometry may look the same, so the impeller, the gas train and the cooling capacity are what a quote has to state.

A bioreactor cell culture process, and its phases

A mammalian process runs in phases and each has its own controls: thaw and expansion through flasks and a seed train, inoculation at a target density, a growth phase where oxygen demand rises and pH is held with carbon dioxide and base, a production phase often at a shifted temperature with feeds added on a schedule or on a measured signal, and harvest at a viability or titre trigger. Writing the triggers down in advance, rather than judging them at the vessel, is what makes two batches comparable.

A disposable bioreactor and what the bag changes

A disposable bioreactor moves the product contact surface into a gamma irradiated bag, so cleaning validation and changeover time disappear and consumable cost per batch appears instead. The comparison against stainless steel is a cost of goods calculation rather than a performance one at small scale. Extractables data, film supply security and the sensor format the bag is pre-fitted with are what the purchase actually turns on.

A stirred tank bioreactor and why it is still the reference

A stirred tank bioreactor is the format most process data exists for, which is why scale up models and regulatory expectations are written around its impeller power per volume and its gas transfer. Its limits are shear on fragile cells and mixing time in large volumes. Geometry ratios rather than vessel litres are what transfer between scales, and a quoted volume without the working volume is not a specification.

A perfusion bioreactor and the retention device that defines it

A perfusion bioreactor holds cells while medium flows through, so the cell retention device, an alternating tangential flow filter or an acoustic or centrifugal separator, is the part that decides whether the run lasts weeks. Medium consumption is the operating cost and it dominates the economics. The productivity claim to compare is grams per litre of reactor per day rather than titre alone.

Common questions

When is microbial expression not an option?

When the product needs human like glycosylation, when it is large and multi domain, or when correct disulphide formation cannot be achieved. Those constraints rule out the cheaper route regardless of economics.

What actually limits microbial scale up?

Oxygen transfer and heat removal, and mixing time in large vessels. Volume is rarely the binding constraint, which is why a process that works in a small fermenter can fail in a plant with different utilities.

Does continuous processing reduce cost?

It can raise productivity per unit volume substantially and reduce facility footprint, while adding control complexity and changing how batches are defined and released. The saving is real and it is not automatic.

What makes a biologic well characterised?

An analytical package extensive enough that product quality attributes are understood and controlled, rather than inferred from process consistency. It is a description of the evidence, not of the molecule.

Browse by service class

• Compare Gene synthesis on advertised prices